Mereo BioPharma Group plc (Mereo) (MREO): Price and Financial Metrics

Mereo BioPharma Group plc (Mereo) (MREO): $2.61

0.04 (-1.51%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

F

Add MREO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#178 of 362

in industry

MREO Price/Volume Stats

Current price $2.61 52-week high $4.36
Prev. close $2.65 52-week low $0.92
Day low $2.59 Volume 192,932
Day high $2.67 Avg. volume 1,612,600
50-day MA $3.34 Dividend yield N/A
200-day MA $2.26 Market Cap 326.21M

MREO Stock Price Chart Interactive Chart >


Mereo BioPharma Group plc (Mereo) (MREO) Company Bio


Mereo BioPharma Group plc (Mereo) operates as a clinical stage biopharmaceutical company. The Company develops medicines for rare and specialty diseases. Mereo serves the healthcare sector globally.


MREO Latest News Stream


Event/Time News Detail
Loading, please wait...

MREO Latest Social Stream


Loading social stream, please wait...

View Full MREO Social Stream

Latest MREO News From Around the Web

Below are the latest news stories about MEREO BIOPHARMA GROUP PLC that investors may wish to consider to help them evaluate MREO as an investment opportunity.

Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates

Ultragenyx (RARE) reports weaker-than-expected third-quarter 2023 results, missing earnings and sales estimates. Management reiterates the 2023 financial outlook.

Yahoo | November 3, 2023

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information. Recent Program Developments Setrusumab (UX143) On October 14, 2023, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (“Mereo” or the “Company”) announced interim data from the Phase 2 portion

Yahoo | October 23, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start off the week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!

William White on InvestorPlace | October 16, 2023

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET NOVATO, Calif., VANCOUVER, British Columbia and LONDON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced interim data from the Phase

Yahoo | October 14, 2023

Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)

NOVATO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI) will be presented at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR) October 13-16, 2023, in Vancouver, British Columbia. Ultragenyx and its collaborators will present late-breaking presentations on new, updated data from the Phase 2 portion of the

Yahoo | October 9, 2023

Read More 'MREO' Stories Here

MREO Price Returns

1-mo -15.81%
3-mo -17.27%
6-mo 37.37%
1-year 148.57%
3-year -20.67%
5-year N/A
YTD 12.99%
2023 208.00%
2022 -53.13%
2021 -55.31%
2020 9.15%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!